Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $44

Benzinga Newsdesk www.benzinga.com Negative 79.9%

Neg 79.9% Neu 0% Pos 0%

Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and lowers the price target from $47 to $44.